Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTINA L FESER

Allopathic & Osteopathic Physicians Dermatology

NPI
1902122096
CMS profile
987138
Location
CLARKSVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$42,036.94

202 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 5 of 5; records 201–202 of 202 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTINA L FESER

NPI 1902122096 · CMS profile ID 987138

Allopathic & Osteopathic Physicians / Dermatology

CLARKSVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–202 of 202 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1902122096?year=2022&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTINA L FESER, NPI 1902122096, CMS profile ID 987138. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–202 of 202 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902122096?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CHRISTINA L FESER, NPI 1902122096, CMS profile ID 987138. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–202 of 202 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902122096?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CHRISTINA L FESER, NPI 1902122096, CMS profile ID 987138, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–202 of 202 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1902122096?year=2022&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

202 matching records · $42,036.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 202 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–202 of 202.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $17.1101/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949230541 CMS
Sun Pharmaceutical Industries Inc. $12.8301/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947744769 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,714.88 66
PY2020 $1,901.14 48
PY2021 $5,449.00 93
PY2022 $42,036.94 202
PY2023 $93,495.77 308
PY2024 $100,177.25 353
PY2025 $135,977.88 384

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $370,050.68 135
PY2024 Recipient $104.58 1
PY2024 Principal investigator $832,527.04 312
PY2023 Principal investigator $586,635.15 227
PY2022 Principal investigator $689,960.22 160
PY2021 Principal investigator $319,512.25 41
PY2020 Principal investigator $305,615.76 31
PY2019 Recipient $70,014.15 2
PY2019 Principal investigator $217,116.57 46

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

135 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202535045
Principal investigator 1 Incyte Corporation $6,600.00 12/19/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240539898
Principal investigator 1 Incyte Corporation $1,100.00 12/19/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540472
Principal investigator 1 Incyte Corporation $6,600.00 12/19/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540475
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539903
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539907
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539911
Principal investigator 1 Eli Lilly and Company $16,661.00 11/25/2025 Non-covered Recipient Entity
EXIMIA RESEARCH ACQUISITION HO
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187881954
Principal investigator 1 Incyte Corporation $2,550.00 11/19/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1240539893
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,000.00 11/19/2025 Non-covered Recipient Entity
EXIMIA RESEARCH ACQUISITION HO
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288517
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $800.00 11/19/2025 Non-covered Recipient Entity
EXIMIA RESEARCH ACQUISITION HO
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288525
Principal investigator 1 Incyte Corporation $80.10 11/14/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539890
Principal investigator 1 ABBVIE INC. $1,862.00 11/12/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202523903
Principal investigator 1 ABBVIE INC. $583.87 11/06/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202523523
Principal investigator 1 ABBVIE INC. $2,275.43 11/06/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202523525
Principal investigator 1 ABBVIE INC. $497.80 11/04/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202521107
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
International Clinical Research
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235996563
Principal investigator 1 ABBVIE INC. $2,396.18 10/15/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202517035
Principal investigator 1 ABBVIE INC. $1,675.00 10/15/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202517037
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 10/15/2025 Non-covered Recipient Entity
EXIMIA RESEARCH ACQUISITION HO
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286975
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 10/15/2025 Non-covered Recipient Entity
EXIMIA RESEARCH ACQUISITION HO
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286977
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 10/15/2025 Non-covered Recipient Entity
EXIMIA RESEARCH ACQUISITION HO
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286979
Principal investigator 1 Novartis Pharmaceuticals Corporation $216.78 10/08/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190307147
Principal investigator 1 Eli Lilly and Company $44,882.00 10/01/2025 Non-covered Recipient Entity
EXIMIA RESEARCH ACQUISITION HO
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187880061
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,624.15 09/19/2025 Non-covered Recipient Entity
EXIMIA RESEARCH ACQUISITION HOLDING LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223285746
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 09/17/2025 Non-covered Recipient Entity
EXIMIA RESEARCH ACQUISITION HOLDING LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223285606
Principal investigator 1 Incyte Corporation $829.80 09/10/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539886
Principal investigator 1 ABBVIE INC. $2,244.52 09/08/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202510216
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,370.50 08/01/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190307149
Principal investigator 1 ABBVIE INC. $3,392.80 07/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202494673
Principal investigator 1 Incyte Corporation $671.00 07/02/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240470230
Principal investigator 1 Incyte Corporation $1,518.00 06/20/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470222
Principal investigator 1 Incyte Corporation $1,214.40 06/20/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470226
Principal investigator 1 SANOFI US SERVICES INC. $15,700.00 06/16/2025 Non-covered Recipient Entity
International Clinical Research Tennessee Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226119894
Principal investigator 1 Incyte Corporation $88.00 06/13/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470214
Principal investigator 1 Incyte Corporation $61.00 06/13/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470216
Principal investigator 1 Incyte Corporation $105.00 06/13/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470220
Principal investigator 1 Incyte Corporation $1,236.60 06/11/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240470224
Principal investigator 1 ABBVIE INC. $500.00 06/05/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202490505
Principal investigator 1 Incyte Corporation $1,538.00 05/14/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470192
Principal investigator 1 Incyte Corporation $1,622.00 05/14/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470202
Principal investigator 1 Incyte Corporation $2,770.00 05/14/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470208
Principal investigator 1 Incyte Corporation $866.80 05/14/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470212
Principal investigator 1 Incyte Corporation $300.00 05/09/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470218
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,925.00 05/07/2025 Non-covered Recipient Entity
INT CLIN RESEARCH TENNESSEE LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223279128
Principal investigator 1 Incyte Corporation $1,750.50 05/02/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240470210
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539806
Principal investigator 1 Incyte Corporation $24.68 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539811
Principal investigator 1 Incyte Corporation $16.18 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539814
Principal investigator 1 Incyte Corporation $16.18 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539820
Principal investigator 1 Incyte Corporation $0.31 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539824
Principal investigator 1 Incyte Corporation $0.31 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539828
Principal investigator 1 Incyte Corporation $4.86 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539837
Principal investigator 1 Incyte Corporation $4.86 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539841
Principal investigator 1 Incyte Corporation $24.68 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539845
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539849
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539853
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539856
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539861
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539866
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539870
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539874
Principal investigator 1 Incyte Corporation $1,058.25 04/24/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240539759
Principal investigator 1 Incyte Corporation $3,570.20 04/18/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema No dispute reported 06/30/2026 1240470196
Principal investigator 1 Incyte Corporation $223.20 04/18/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema No dispute reported 06/30/2026 1240470198
Principal investigator 1 Incyte Corporation $1,533.60 04/11/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470194
Principal investigator 1 Incyte Corporation $1,209.60 04/09/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240470228
Principal investigator 1 Incyte Corporation $3,658.80 04/08/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539747
Principal investigator 1 Incyte Corporation $1,804.00 04/07/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240470200
Principal investigator 1 Incyte Corporation $84.00 04/07/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240470204
Principal investigator 1 Incyte Corporation $1,294.70 04/07/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240470206
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 04/04/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277602
Principal investigator 1 ABBVIE INC. $3,494.20 04/03/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202472710
Principal investigator 1 Incyte Corporation $54.76 04/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539763
Principal investigator 1 Incyte Corporation $49.36 04/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539767
Principal investigator 1 Incyte Corporation $64.72 04/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539771
Principal investigator 1 Incyte Corporation $68.70 04/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539776
Principal investigator 1 Incyte Corporation $49.32 04/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539781
Principal investigator 1 Incyte Corporation $14.84 04/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539785
Principal investigator 1 Incyte Corporation $59.13 04/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539789
Principal investigator 1 Incyte Corporation $49.32 04/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539794
Principal investigator 1 Incyte Corporation $62.27 04/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539798
Principal investigator 1 Incyte Corporation $135.40 04/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539801
Principal investigator 1 Incyte Corporation $12.36 04/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539832
Principal investigator 1 Incyte Corporation $49.32 04/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539878
Principal investigator 1 Incyte Corporation $49.32 04/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539881
Principal investigator 1 Incyte Corporation $550.00 04/01/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240539751
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,252.55 03/26/2025 Non-covered Recipient Entity
INT CLIN RESEARCH TENNESSEE LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223277045
Principal investigator 1 Eli Lilly and Company $1,162.80 03/25/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187883230
Principal investigator 1 Incyte Corporation $1,384.20 03/19/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470176
Principal investigator 1 Incyte Corporation $6,600.00 03/11/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539688
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 03/07/2025 Non-covered Recipient Entity
INT CLIN RESEARCH TENNESSEE LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223276123
Principal investigator 1 Incyte Corporation $1,565.10 03/03/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470180
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240539739
Principal investigator 1 Incyte Corporation $22.90 03/03/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240539742
Principal investigator 1 Incyte Corporation $1,538.00 02/21/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470168
Principal investigator 1 Incyte Corporation $1,411.30 02/21/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470170
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,177.20 02/21/2025 Non-covered Recipient Entity
INT CLIN RESEARCH TENNESSEE LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223275469
Principal investigator 1 ABBVIE INC. $500.00 02/20/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202453190
Principal investigator 1 Incyte Corporation $1,209.60 02/10/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240470178
Principal investigator 1 Incyte Corporation $1,311.20 02/05/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240470184
Principal investigator 1 Incyte Corporation $1,639.00 02/05/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240470186
Principal investigator 1 Incyte Corporation $4.25 02/05/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240539694
Principal investigator 1 Incyte Corporation $93.30 02/05/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240539697
Principal investigator 1 Incyte Corporation $155.50 02/05/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240539723
Principal investigator 1 Incyte Corporation $77.75 02/05/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240539727
Principal investigator 1 Incyte Corporation $52.48 02/05/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240539731
Principal investigator 1 Incyte Corporation $6.22 02/05/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240539735
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,923.35 02/05/2025 Non-covered Recipient Entity
INT CLIN RESEARCH TENNESSEE LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223274837
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,555.00 02/03/2025 Non-covered Recipient Entity
INT CLIN RESEARCH TENNESSEE LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274653
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $20,044.83 01/29/2025 Non-covered Recipient Entity
International Clinical Research
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1235996565
Principal investigator 1 Incyte Corporation $87.00 01/24/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema No dispute reported 06/30/2026 1240470172
Principal investigator 1 Incyte Corporation $1,645.20 01/24/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470174
Principal investigator 1 Incyte Corporation $7,981.42 01/23/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240539755
Principal investigator 1 Incyte Corporation $1,000.00 01/17/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540483
Principal investigator 1 Incyte Corporation $10,000.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540479
Principal investigator 1 Incyte Corporation $1,500.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540488
Principal investigator 1 Eli Lilly and Company $68,195.00 01/08/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187882180
Principal investigator 1 Incyte Corporation $86.00 01/08/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470166
Principal investigator 1 Incyte Corporation $61.00 01/08/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470182
Principal investigator 1 Incyte Corporation $1,146.60 01/08/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240470188
Principal investigator 1 Incyte Corporation $105.00 01/08/2025 Covered Recipient Teaching Hospital
Beth Israel Deaconess Medical Center
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240470190
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,854.50 01/08/2025 Non-covered Recipient Entity
INT CLIN RESEARCH TENNESSEE LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223273789
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 01/08/2025 Non-covered Recipient Entity
INT CLIN RESEARCH TENNESSEE LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223273791
Principal investigator 1 Eli Lilly and Company $3,646.80 01/07/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187881988
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $450.00 01/03/2025 Non-covered Recipient Entity
INT CLIN RESEARCH TENNESSEE LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223273525
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,008.50 01/03/2025 Non-covered Recipient Entity
INT CLIN RESEARCH TENNESSEE LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223273527
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $97.50 01/03/2025 Non-covered Recipient Entity
INT CLIN RESEARCH TENNESSEE LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223273529
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,050.00 01/03/2025 Non-covered Recipient Entity
INT CLIN RESEARCH TENNESSEE LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223273531
Principal investigator 1 Incyte Corporation $84.80 01/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539690
Principal investigator 1 Incyte Corporation $339.20 01/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539701
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539705
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539709
Principal investigator 1 Incyte Corporation $69.94 01/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539714
Principal investigator 1 Incyte Corporation $106.00 01/02/2025 Non-covered Recipient Entity
INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539718